XTLB
Closed
Xtl Biopharmaceuticals Ltd Adr
2.7
0.0 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 2.7
Day's Range: 2.5912 - 2.7
Send
sign up or login to leave a comment!
When Written:
1.27
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company that develops drugs for the treatment of autoimmune diseases and viral infections. The company's lead product candidate, hCDR1, is a novel drug candidate for the treatment of systemic lupus erythematosus (SLE), a chronic autoimmune disease. XTL is also developing a second product candidate, rHuEPO, for the treatment of hepatitis C virus (HCV) infection. The company is headquartered in Ra'anana, Israel and trades on the NASDAQ under the ticker symbol "XTLB". As of August 2021, XTL Biopharmaceuticals Ltd had a market capitalization of approximately $37 million.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
1.27
XTL Biopharmaceuticals Ltd ADR is a biopharmaceutical company that focuses on the development of drugs for the treatment of autoimmune diseases, viral infections, and cancer. The company's lead product candidate, hCDR1, is a novel therapeutic peptide that has shown promising results in clinical trials for the treatment of systemic lupus erythematosus (SLE) and Sjogren's syndrome. XTL Biopharmaceuticals Ltd ADR is headquartered in Israel and is listed on the NASDAQ stock exchange under the ticker symbol XTLB.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!